Skip to main content
 
  • Moderna to Build State-of-the-Art Fully Integrated GMP mRNA Clinical Manufacturing Facility in Norwood, Mass.

    “We are thrilled to announce the site selection for our GMP manufacturing facility, as this is a critical component of the early development engine we are building to advance many mRNA programs in parallel in human clinical studies … Our Norwood facility will enable us to deliver our mRNA therapies and vaccines quickly, which will support rapid progression from development candidate nomination to human proof-of-concept.”

    Stéphane Bancel, Chief Executive Officer of Moderna

  • Moderna's Early Development Engine

    Moderna’s Early Development Engine

    We are building a sophisticated early development engine to enable Moderna and our partners to advance many mRNA programs in parallel from development candidate nomination through human proof-of-concept data.

  • Moderna Enters New Growth Phase with Closing of $474M Equity Financing

    Moderna Enters New Growth Phase with Closing of $474 Million Equity Financing and its First BARDA Grant for up to $125 Million for Zika mRNA Vaccine

    “Moderna is, yet again in its short five years, accelerating its expansion and entering a new growth phase. We are pivoting toward a new chapter in our company’s history, and we feel privileged to deploy our substantial capital resources to advance our mission to deliver on the promise of mRNA therapeutics as an entire new class of medicines.”

    Stéphane Bancel, Chief Executive Officer of Moderna

  • Moderna Announces Funding Award from BARDA to Accelerate Development of Zika mRNA Vaccine

    Moderna Announces Funding Award from BARDA to Accelerate Development of Zika mRNA Vaccine

    Initial $8.2 million base award with funding options for up to $125 million IND filing anticipated by end of year

  • How Moderna's mRNA Vaccines Work

    How Moderna’s mRNA Vaccines Work

    Our infectious disease vaccines deploy mRNA to enable the immune system to prevent disease.

  • Moderna Therapeutics Provides Mid-Year Corporate Update, Announces Continued Clinical Development Progress and Pipeline Acceleration

    Eleven mRNA-based development candidates nominated to date across ventures and partners

    • Two Phase 1 studies underway for mRNA-based infectious disease vaccines
    • CTA filed for Phase 1 study of AZD8601, AstraZeneca’s investigational mRNA-based Therapeutic that encodes for VEGF-A
    • Eight candidates advancing through IND-enabling studies

    Several additional clinical studies planned to initiate in 2016

Our Mission

Deliver on the promise of mRNA science to create a new generation of transformative medicines for patients.

Tweets